Share This Author
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.
A human memory T-cell subset with stem cell-like properties
A long-lived human memory T cell population that has an enhanced capacity for self-renewal and a multipotent ability to derive central memory, effector memory and effector T cells is described.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
- D. Porter, B. Levine, M. Kalos, A. Bagg, C. June
- Biology, MedicineNew England Journal of Medicine
- 24 August 2011
A low dose of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL).
Cytokine release syndrome in severe COVID-19
Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease In December 2019, a new strain of coronavirus, severe acute respiratory syndrome–coronavirus 2…
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
It is suggested that colocalization of PD-1 with CD3 and/or CD28 may be necessary for inhibition of T cell activation, and that recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, and not the adaptor SRC homology 2 domain -containing molecule 1A, to the ITSM domain is needed.
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
The in vivo expansion of theCAR T cells correlated with clinical responses, and the CAR T cells persisted and remained functional beyond 4 years in the first two patients achieving CR, suggesting that disease eradication may be possible in some patients with advanced CLL.